CTOs on the Move

Acreage Holdings

www.acreageholdings.com

 
Headquartered in New York City, Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company`s national retail store ‎brand, The Botanist. Acreage`s wide range of national and regionally available cannabis products include the award-winning Botanist brand, the highly recognizable Tweed brand, the Prime medical brand in Pennsylvania, the Innocent edibles brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Funding

Acreage Holdings raised $119M on 07/23/2018
Acreage Holdings raised $30M on 02/10/2020
Acreage Holdings raised $15M on 06/17/2020
Acreage Holdings raised $28M on 11/03/2020
Acreage Holdings raised $33M on 09/29/2020

Similar Companies

Elevation Spine

Elevation Spine is a medical device company with a proprietary technology platform, Saber Technology, which is an advanced and differentiated approach to spinal fusion. The fusion procedure is highly efficient while remaining minimally invasive.

Womens International Pharmacy

Womens International Pharmacy is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SSCI

SSCI is a West Lafayette, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chimerix

Excerpted from the website: Chimerix discovers, develops and commercializes orally-available, antiviral therapeutics for a broad range of viral diseases, including cytomegalovirus, multi-drug resistant HIV infection and human papilomavirus.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.